Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels by Lai, CL et al.
Title
Risk for hepatocellular carcinoma with respect to hepatitis B
virus genotypes B/C, specific mutations of enhancer II/core
promoter/precore regions and HBV DNA levels
Author(s) Yuen, MF; Tanaka, Y; Shinkai, N; Poon, RT; But, DYK; Fong,DYT; Fung, J; Wong, DKH; Yuen, JCH; Mizokami, M; Lai, CL
Citation Gut, 2008, v. 57 n. 1, p. 98-102
Issued Date 2008
URL http://hdl.handle.net/10722/57531
Rights Gut. Copyright © B M J Publishing Group.
doi:10.1136/gut.2007.119859 
 2008;57;98-102; originally published online 4 May 2007; Gut
  
D Ka-Ho Wong, J Chi-Hang Yuen, M Mizokami and C-L Lai 
M-F Yuen, Y Tanaka, N Shinkai, R T Poon, D Yiu-Kuen But, D Y-T Fong, J Fung,
  
 regions and HBV DNA levels
mutations of enhancer II/core promoter/precore
hepatitis B virus genotypes B/C, specific 
Risk for hepatocellular carcinoma with respect to
 http://gut.bmj.com/cgi/content/full/57/1/98
Updated information and services can be found at: 
 These include:
 References
 http://gut.bmj.com/cgi/content/full/57/1/98#otherarticles
1 online articles that cite this article can be accessed at: 
  
 http://gut.bmj.com/cgi/content/full/57/1/98#BIBL
This article cites 33 articles, 8 of which can be accessed free at: 
 service
Email alerting
the top right corner of the article 
Receive free email alerts when new articles cite this article - sign up in the box at
 Notes   
 http://journals.bmj.com/cgi/reprintform
To order reprints of this article go to: 
 http://journals.bmj.com/subscriptions/
 go to: GutTo subscribe to 
 on 21 October 2008 gut.bmj.comDownloaded from 
Risk for hepatocellular carcinoma with respect to
hepatitis B virus genotypes B/C, specific mutations
of enhancer II/core promoter/precore regions and
HBV DNA levels
M-F Yuen,1 Y Tanaka,2 N Shinkai,2 R T Poon,3 D Yiu-Kuen But,1 D Y-T Fong,4 J Fung,1
D Ka-Ho Wong,1 J Chi-Hang Yuen,1 M Mizokami,2 C-L Lai1
1 Department of Medicine, The
University of Hong Kong, Queen
Mary Hospital, Hong Kong;
2 Department of Clinical
Molecular Informative Medicine,
Nagoya City University Graduate
School of Medical Sciences,
Nagoya, Japan; 3 Department of
Surgery, The University of Hong
Kong, Queen Mary Hospital,
Hong Kong; 4 Department of
Nursing Studies, The University
of Hong Kong, Queen Mary
Hospital, Hong Kong
Correspondence to:
Dr M F Yuen, Department of
Medicine, The University of
Hong Kong, Queen Mary
Hospital, Pokfulam Road, Hong
Kong; mfyuen@hkucc.hku.hk
Revised 20 April 2007
Accepted 24 April 2007
Published Online First
3 May 2007
ABSTRACT
Background/aim: To examine the risks for hepatocellular
carcinoma (HCC) with respect to hepatitis B virus (HBV)
genotypes, specific viral mutations (MT), serum HBV DNA
levels, and cirrhosis.
Methods: HBV genotypes, 1653/1753/core promoter
(CP)/precore MT and HBV DNA levels were determined in
248 HBV patients with HCC and 248 HBV controls.
Results: Genotype C, CP-MT, T1653, HBV DNA levels>4
log10 copies/ml and cirrhosis had a higher risk for HCC
compared to patients with genotype B (p = 0.001, OR
1.9), CP wild-type (WT) (p,0.001, OR 4.1), C1653
(p = 0.028, OR 2.4), HBV DNA ,4 log10 copies/ml
(p = 0.003, OR 2.1) and without cirrhosis (p,0.001, OR
4.0) respectively. Multivariate analysis showed that CP-
MT, T1653, HBV DNA >4 log10 copies/ml and cirrhosis
were independent factors for HCC (all p,0.05). A
receiver operating characteristics curve showed no cut-off
HBV DNA level associated with minimal chance of HCC.
Patients with CP-MT and cirrhosis had a 22.2-fold
increased risk of HCC compared to patients with CP-WT
and without cirrhosis. Patients with CP-MT and HBV DNA
levels >4 log10 copies/ml had a 7.2-fold increased risk of
HCC compared to patients with CP-WT and HBV DNA
levels ,4 log10 copies/ml. Patients with CP-MT and
T1653 had a 9.9-fold increased risk of HCC compared to
patients with wild-type for both regions.
Conclusions: CP-MT, T1653, HBV DNA levels >4 log10
copies/ml and cirrhosis are independent factors for
development of HCC. The risks increased substantially in
patients having these factors in combination.
Hepatocellular carcinoma (HCC) is a disease of
global concern, occurring in over 20% of the 400
million people with chronic hepatitis B infection
(CHB). While the exact mechanisms of hepatocar-
cinogenesis with CHB infection remain elusive,
several virological factors have been identified to be
possibly associated with a higher risk of develop-
ment of HCC. These include hepatitis B virus load
(HBV DNA) levels, HBV genotypes, core promoter
and precore mutations. These factors are also
associated with the development of cirrhosis and
its complications.1 2
The majority of the published studies examining
HBV genotypes compare genotypes B and C in
relation to the disease profile of CHB because these
are the two main genotypes prevailing in Asia, a
region contributing around 75% of the world’s
population of CHB. However, while some studies
suggest genotype C has a higher risk of develop-
ment of HCC,3–5 this observation is not substan-
tiated by others.6–8 One large study conducted in
Taiwan shows that genotype B is more commonly
found in patients with HCC developed at a young
age.9 In the Caucasian and Indian populations,
genotype D is associated with a greater risk for
HCC than genotype A.
Concerning the common naturally occurring
mutations at the precore (G1896A) and core
promoter (A1762T and G1764A) regions, some
studies show that patients with precore mutants
have more aggressive disease including reactivation
of CHB and fulminating course of the disease,10 11
These observations have not been substantiated in
other studies partly because the predominant
genotypes are different between Asia and Europe/
USA.12 13 For core promoter mutations, some
studies report a higher risk of development of
HCC in patients with core promoter mutations
compared to those with wild-type.3 6 7 14–16 Again,
this has not been confirmed by other studies.5 17 In
addition to these two common mutations, two
other mutations, C to T at 1653 in the enhancer II
region and T to C/A/G (V) at 1753 in the core
promoter region, have recently been found to be
associated with the development of HCC.18–20
The uncertainty as to whether these virological
factors are genuine risk factors for the development
of HCC may be due to several reasons. Most of the
studies only have a limited number of patients.
These studies often examine only specific virologi-
cal factors; for example, genotypes without con-
sidering the possible confounding effect of other
parameters, such as viral mutations and HBV DNA
levels. Indeed the associations between genotype B
with precore mutations and genotype C with core
promoter mutations have been shown to be
confounding factors.21 Whether there are any
additive or synergistic effects on the risks of HCC
development with different combinations of geno-
types/precore/core promoter and mutations in the
enhancer II region and HBV DNA levels have not
been studied. Finally, the risks for development of
HCC of these factors in the setting of cirrhosis
have not been examined.
Therefore we sought to examine the risks of
HBV DNA levels, HBV genotypes, core promoter/
precore/T1653/V1753 mutations and cirrhosis
individually and in combination for the develop-
ment of HCC in a large population study.
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PATIENTS AND METHODS
Patients
A total of consecutive 248 Chinese CHB patients with HCC
were recruited from Department of Medicine and Department
of Surgery, The University of Hong Kong, Queen Mary
Hospital, Hong Kong from 2000 to 2004. All patients had the
diagnosis of HCC for the first time, during regular follow-up in
our centre (n = 198) or in other hospitals (n = 50). Patients with
recurrent HCC were excluded from the present study. One
hundred and twenty patients had histologically proven HCC.
The remaining 128 patients had elevated a-fetoprotein (AFP)
with typical imaging features in computerised tomography and/
or magnetic resonance imaging and/or hepatic angiogram.
During the same period of recruitment of patients with HCC,
4825 CHB Chinese patients without HCC were being followed
up in the University Liver Clinic of Queen Mary Hospital, Hong
Kong. A consecutive 248 CHB patients without HCC were
recruited as controls. These control patients were matched
individually with each patient with HCC for gender, age (less
than 2 years difference) and hepatitis B e antigen (HBeAg)/
antibody to HBeAg (anti-HBe) status in a 1:1 ratio. The absence
of HCC was assured by the absence of any space occupying
lesion by ultrasonography performed on two separate occasions
1 year apart.
All patients were positive for hepatitis B surface antigen
(HBsAg) checked by radioimmunoassay (AUSRIA II, Abbott
Laboratories, North Chicago, IL) for at least 6 months. HBeAg/
anti-HBe was also determined by the same assay. Patients with
other concomitant diseases including hepatitis C or D virus
infection, autoimmune hepatitis, Wilson’s disease, primary
biliary cirrhosis, alcoholic liver disease and fatty liver (diagnosed
by ultrasonography) were excluded.
Liver cirrhosis is defined by the score of .2 according to the
aspartate aminotransferase (AST) to platelet ratio index (APRI)
calculated from the following formula: ([AST/upper limit of
normal]/platelet count [6109/litre]) 6 100.22
Methods
Stored serum at 270uC were thawed for the determination of
the HBV DNA levels, HBV genotypes, core promoter and
precore mutations and finally the mutations at the enhancer II
region. The HBV DNA levels were measured by Cobas Amplicor
HBV Monitor test (Roche Diagnostics, Branchburg, NJ) with a
lower limit of detection of 300 copies/ml.
HBV genotypes were determined by the enzyme linked
immunosorbent assay (ELISA). The detailed methodology of the
assay was described in our previous study.23 The sequence of
core promoter and precore regions including A1762T/G1764A
(core promoter mutations) and G1896A (precore mutation)
were determined by direct sequencing. The methodology was
described in our previous study.20 The two recently identified
HCC-related mutations at the enhancer II and core promoter
regions namely, C to T at 1653 and T to C/A/G (V) at 1753,
were also sequenced according to the methods described in our
previous study20 in 140 patients with HCC and 100 control
patients with adequate sera available for sequencing. There
were no differences in the median age (range), male to female
and HBeAg: anti-HBe ratios between these two subgroups of
140 and 100 patients [56.6 years (29–83.7) vs. 59.8 years (24.8–
81.6), p = 0.13 for age; 114:26 vs. 79: 21, p = 0.65 for male to
female ratio; and 40:100 vs. 23:77, p = 0.28 for HBeAg: anti-HBe
ratio).
Statistical analysis
All statistical analyses were performed using the SPSS 14.0 for
Windows, SPSS Inc., Chicago, IL). The Mann–Whitney U test
was used to compare continuous variables between patients
with HCC and control patients. The x2 test with Yates
correction factor or Fisher’s exact test was used to compare
categorical variables between two groups. A receiver operating
characteristic (ROC) curve was used to determine whether
there is a cut-off HBV DNA which was associated with no risk
of HCC. Logistic regression was adopted to determine
independent risk factors for HCC. The adjusted odds ratios
(OR) for development of HCC of different combinations of
variables were also calculated by the logistic regression analysis
with a selected combination defined as the reference. All
estimates were accompanied by a 95% confidence interval
(CI), where appropriate and a p-value ,0.05 was considered as
statistical significance.
RESULTS
Demographics
The demographic data for 248 patients with HCC and 248
control patients are listed in table 1. Patients with HCC had a
significantly poorer liver biochemical parameters and higher
median AFP level compared to control patients. Patients with
HCC also had a higher prevalence of liver cirrhosis compared to
control patients. The OR for patients with cirrhosis was 4.0
[95% CI, 2.8 to 5.9].
HBV genotypes
A total of 478 out of 496 (96.2%) samples had positive genotype
results from EIA test, but this test gave indeterminate results for
the remaining 18 samples (10 from patients with HCC, eight
from control patients). Of the 238 patients with HCC with
genotype results, 67 (28.2%) had genotypes B, 170 (71.4%) had
genotypes C and one (0.4%) had genotype D. Of the 240 control
patients with genotype results, 100 (41.7%) had genotypes B,
135 (56.3%) had genotype C, three (1.3%) had genotypes D and
two (0.8%) had mixed genotypes.
Comparing patients with either genotypes B or C, patients
with HCC had a higher prevalence of genotype C compared to
control patients [170/237 (71.2%) vs. 135/235 (57.4%) respec-
tively; p = 0.001; OR 1.9; 95% CI, 1.3 to 2.8].
Core promoter and precore mutations
Of all the 496 samples, direct sequencing failed to generate
results for 70 samples for core promoter region and 61 samples
for precore region.
Table 1 Demographic data for the study population
Patients with HCC
(n = 248) Control patients (n = 248)
Sex (M:F) 199:49 199:49
Age (years) 57.5 (24.8–83.7) 57.7 (24.8–81.8)
HBeAg:anti-HBe (%) 61:187 (24.6%:75.4%) 61:187 (24.6%:75.4%)
Albumin (g/l) 37 (16–59)* 43 (17–53)*
Bilirubin (mmol/l) 17 (5–531){ 12 (2–96){
ALT (U/l) 57 (4–1154){ 46 (9–920){
AFP (ng/ml) 136.5 (1–1 060 000)1 5 (1–200)1
Presence of cirrhosis (%) 170 (68.5%)" 87 (35.1%)"
*,{,{,1,"p,0.001.
Continuous variables are expressed in median (range).
ALT, alanine aminotransferase; AFF, a-fetoprotein.
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Results of core promoter mutations were successfully
obtained in 194 (78.2%) samples of patients with HCC and in
232 (93.5%) samples of control patients. Patients with HCC had
a higher prevalence of core promoter mutations compared to
patients without HCC [173/194 (89.2%) vs. 155/232 (66.8%),
respectively; p,0.001; OR, 4.1 (95% CI, 2.4 to 6.9)].
Results of precore mutations were successfully obtained by
the direct sequencing in 198 (79.8%) samples of patients with
HCC and in 237 (95.6%) samples of patients without HCC.
There was no significant difference in the prevalence of precore
mutations between patients with and without HCC [72/198
(36.4%) vs. 106/237 (44.7%), respectively; p = 0.10].
Relationship between HBV genotypes and core promoter/precore
mutations
Patients with genotype B had a higher chance of harbouring
precore mutations compared to patients with genotype C [105/
144 (72.9%) vs. 67/267 (25.1%), respectively; p,0.001; OR, 8.0;
95% CI, 5.1 to 12.7)]. Patients with genotype C had a higher
chance of harbouring core promoter mutations compared to
patients with genotype B [237/264 (89.8%) vs. 76/141 (53.9%),
respectively; p,0.001; OR, 7.5; 95% CI, 4.5 to 12.6].
HBV DNA levels
To determine whether there is an exact HBV DNA level below
which HCC is unlikely to occur, the HBV DNA levels of all the
patients with or without HCC were entered in the ROC curve
analysis (fig. 1). The ROC nearly overlapped with reference line
with the area under the curve (AUC) of 0.51 (p = 0.75; 95% CI,
0.46 to 0.56) indicating that there existed no cut-off HBV DNA
level that was associated with minimal risk of HCC. Further
separate analysis of patients who had HBeAg seroconversion
(anti-HBe positive) with less fluctuation of HBV DNA levels
during the course of the disease was performed. The AUC was
only 0.56 (p = 0.054; 95% CI, 0.50 to 0.62). This suboptimal
value confirmed that there was no HBV DNA level that was
associated with minimal risk of HCC even for anti-HBe-positive
patients.
Though a ‘‘safe’’ lower limit of HBV DNA level could not be
identified, a higher proportion of patients with HCC had high
viral load defined by HBV DNA level >4 log10 copies/ml
compared to that of control patients [218/248 (87.9%) vs. 193/
248 (77.8%), respectively; p = 0.003; OR, 2.1; 95% CI, 1.3 to
3.4].
T1653 and V1753 mutations
Results of T1653 and V1753 were successfully obtained by the
direct sequencing in 133 (95%) out of 140 samples of patients
with HCC and in 99 out of 100 (99%) samples of control
patients. The reason for samples with no obtainable results for
these two mutations was due to the failure of generation of
sequence with good quality by direct sequencing. Patients with
HCC had a significantly higher prevalence of T1653 mutations
compared to control patients [19.5% (26/133) vs. 9.1% (9/99),
respectively; p = 0.028; OR, 2.4; 95% CI, 1.1 to 5.4]. There was
no difference in the prevalence of T1753 mutations between
patients with HCC and control patients [42.1% (56/133) vs.
44.4% (44/99), respectively; p = 0.72].
Multivariate analysis on the risk factors for HCC
HBV genotypes, core promoter mutations, T1653 mutations,
HBV DNA levels and presence of cirrhosis were entered into the
logistic regression analysis. Core promoter mutations, T1653
mutation, HBV DNA levels >4 log10 copies/ml and presence of
cirrhosis were shown to be independent factors associated with
HCC (p = 0.015, 0.044, 0.048 and 0.005, respectively). Genotype
C, identified as a significant risk factor in the univariate analysis
was not an independent risk factor for HCC.
Relationship between core promoter mutations, T1653
mutations, HBV DNA levels and cirrhosis
A higher proportion of patients with core promoter mutations
had high viral load (HBV DNA >4 log10 copies/ml) compared to
that of patients without core promoter mutations [284/328
(86.6%) vs. 71/98 (72.4%), respectively; p = 0.001; OR, 2.6; 95%
CI, 1.4 to 4.2]. There was no difference in the prevalence of
T1653 mutation between patients with core promoter muta-
tions and wild-type [28/174 (16.1%) vs. 6/43 (14.0%), respec-
tively; p = 0.91]. Patients with core promoter mutations had a
significantly higher prevalence of cirrhosis compared to patients
with core promoter wild-type [177/328 (54.0%) vs. 39/98
(39.8%), respectively; p = 0.014; OR, 1.8; 95% CI, 1.1 to 2.8].
Adjusted risks for patients with core promoter mutations
stratified according to HBV DNA levels, 1653 mutations and
cirrhosis
Stratifying core promoter mutations, 1653 mutations, HBV
DNA levels and presence of cirrhosis to assess the combined risk
for the development of HCC resulted in 16 different groups of
patients with certain groups having fewer than five patients,
thus precluding reliable statistical analysis. Therefore separate
analyses were performed by stratifying (1) core promoter
mutations according to HBV DNA levels, (2) core promoter
mutations with or without concomitant 1653 mutations and
(3) core promoter mutations according to presence or absence of
cirrhosis. The adjusted odds ratios for the development of HCC
are shown in tables 2, 3 and 4, respectively.
DISCUSSION
To our knowledge, the present study is the largest study
examining the individual role as well as the possible interacting
effects of HBV genotypes, the two commonly occurring
mutations (core promoter and precore mutations), mutations
at the enhancer II (T1653) and at the more upstream core
promoter region (V1753), HBV DNA levels, and liver cirrhosis
Figure 1 Receiver operating characteristics curve (ROC) of HBV DNA
levels and development of HCC (area under curve = 0.51) (p = 0.75;
95% CI, 0.46 to 0.56).
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on the development of HCC. This relatively large number of
patients would allow any possible links or associations between
these factors contributing to the development of HCC to be
defined more unequivocally. One of the limitations of the
present study is that the role of deletions in the pre-S region of
HBV genome which have been recently shown to be associated
with the development of HCC has not been studied.24
An epiphenomenon observed in the present study was the
higher risk of HCC in patients with genotype C compared to
patients with genotype B (all were subgenotype B2 in our
locality according to our previous study).25 This is apparently
consistent with other studies.3–5 However, genotype C was not
found to be an independent factor for HCC when tested in the
multivariate analysis. Core promoter mutations, T1653 muta-
tions, high HBV DNA levels and presence of cirrhosis were
independent risk factors for HCC. This is not an unusual
finding because of the strong association of genotype C with
core promoter mutations (89.8%), and genotype B with precore
mutations (72.9%). Though it is well proven that patients with
genotype B have an earlier HBeAg seroconversion,21 26 it appears
neither genotype B nor C has any major influential effects on
the life-time risk of HCC, a finding in concordance with other
studies.6 27 We have recently shown that the earlier HBeAg
seroconversion with genotype B is related to the more intense
immunogenic stimulation during the immunoclearance phase.28
The effects exerted by HBV genotypes B and C on the disease
progression of CHB subsequent to HBeAg seroconversion
appear to be similar.
However, there are at least two documented effects
accompanying core promoter mutations on the development
of HCC. Mutations in the core promoter region result in a shift
change of the viral pregenomic secondary structure which may
enhance the viral replication.29 Viral replication can also be
further enhanced by a second mechanism in which the
transcription of the pregenomic RNA will be increased through
the removal of the nuclear receptor binding site and creation of
a hepatocytes nuclear binding factor.30 These changes increase
the core RNA transcription with enhanced core protein, DNA
polymerase, pre-genomic RNA synthesis, but suppress the
precore RNA transcription whose normal function is to decrease
pregenomic RNA packaging.31 32 This is in complete concordance
with the finding of the present study and of Chauhan and
colleagues.33 HBV DNA levels were higher in patients with core
promoter mutations compared to those without core promoter
mutations.
In the present study, by setting the patients without core
promoter mutations and HBV DNA ,4 log10 copies/ml as a
reference, the adjusted odds ratio for HCC for patients with
core promoter mutations at the same viraemic level was 3.1
(95% CI, 0.9 to 10.6), with a borderline p value of 0.07 (table 2).
It is possible that the higher risk of HCC in patients with core
promoter mutations may also be mediated through another
additional pathway independent of the increase in viral
replication. The possible carcinogenic mechanisms require
further in vitro studies and functional analyses to delineate.
The present study demonstrated that the risk of HCC was
substantially increased in patients harbouring core promoter
mutations and having liver cirrhosis, a 22.2-fold increase when
compared to patients with core promoter wild-type and
without cirrhosis (table 4). Similarly, patients with core
promoter mutations with high HBV DNA levels of >4 log10
copies/ml had a 7.2-fold increase risk of HCC when compared to
patients with core promoter wild-type with HBV DNA levels
,4 log10 copies/ml (table 2).
In the present study, we found that T1653 was an
independent risk factor for the development of HCC.
According to our previous studies,20 34 T1653 mutation is
associated with HCC in patients with genotype C. In the
present study, we further confirmed with larger number of
patients that T1653 was an independent risk factor for HCC
irrespective of HBV genotypes. 1653 is located in the box alpha
of the enhancer II region of HBV genome. The C to T mutation
at 1653 converts histidine to tyrosine at amino acid 94 of the X
protein which may explain its association with the hepatocar-
cinogenesis. According to Takahashi and colleagues, the
frequency of T1653 mutation increases with the progression
of liver disease from chronic hepatitis to cirrhosis.19 It occurs
later than, and independent of, core promoter mutations in
chronic hepatitis B disease. However, when both viral mutations,
that is, core promoter and T1653 mutations, co-existed, the risk of
HCC was substantially increased to 9.9-fold when compared to
patients with wild-type at both genomic regions (table 3).
Finally, the present study showed that there was no reliable
cut-off HBV DNA level associated with low risk of HCC. This
means that maximal viral suppression to the lowest possible
HBV DNA levels should be the target for future management of
CHB disease.
In conclusion, core promoter mutations, T1653 mutations,
HBV DNA levels >4 log10 copies/ml and presence of cirrhosis
were independent factors for the development of HCC. The risk
increased substantially in patients who carried these factors in
combination. Future studies should consider these factors in
conjunction with age and gender of patients to formulate the
risk of HCC in CHB patients.
Competing interests: None.
Table 2 Adjusted odds ratios for HCC in patients with core promoter
wild-type/mutations according to the HBV DNA levels
Core
promoter
HBV DNA
(log10 copies/ml)
Number of
patients
Odds ratio
(95% CI) p Value
Wild-type ,4 27 Reference –
Wild-type >4 77 1.8 (0.6 to 6.0) 0.33
Mutant ,4 44 3.1 (0.9 to 10.6) 0.07
Mutant >4 426 7.2 (2.4 to 21.4) ,0.001
CI, confidence interval.
Table 3 Adjusted odds ratios for HCC in patients with core promoter
wild-type/mutations according mutations at 1653
Core
promoter 1653
Number of
patients Odds ratio (95% CI) p Value
Wild-type Wild-type 37 Reference –
Wild-type Mutant 6 2.7 (0.5 to 15.6) 0.27
Mutant Wild-type 146 3.6 (1.6 to 7.9) 0.02
Mutant Mutant 28 9.9 (3.1 to 31.5) ,0.001
CI, confidence interval.
Table 4 Adjusted odds ratios for HCC in patients with core promoter
wild-type/mutations according presence or absence of cirrhosis
Core
promoter Cirrhosis
Number of
patients Odds ratio (95% CI) p Value
Wild-type No 59 Reference –
Wild-type Yes 39 7.5 (2.5 to 23.0) ,0.001
Mutant No 151 6.0 (2.3 to 15.9) ,0.001
Mutant Yes 177 22.2 (8.4 to 58.4) ,0.001
CI, confidence interval.
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